The regulatory role of PDE4B in the progression of inflammatory function study

Abstract

Inflammation is a response of the body to external stimuli (eg. chemical irritants, bacteria, viruses, etc.), and when the stimuli are persistent, they tend to trigger chronic inflammation. The presence of chronic inflammation is an important component of the tumor microenvironment produced by a variety of inflammatory cells (eg. macrophages, neutrophils, leukocytes, etc.). The relationship between chronic inflammation and cancer development has been widely accepted, and chronic inflammation has been associated with the development of many cancers, including chronic bronchitis and lung cancer, cystitis inducing bladder cancer. Moreover, chronic colorectitis is more likely to develop into colorectal cancer. Therefore, the specific relationship and cellular mechanisms between inflammation and cancer are a hot topic of research. Recent studies have identified phosphodiesterase 4B (PDE4B), a member of the phosphodiesterase (PDEs) protein family, as a major cyclic AMP (cAMP) metabolizing enzyme in inflammatory cells, and the therapeutic role of PDE4B as chronic inflammation, cancer. In this review, we will present the tumors associated with chronic inflammation, and PDE4B potential clinical application.

Keywords: CRISPR/Cas9; PDE4B; cancer; cellular signaling pathways; inflammation.

FIGURE 1

Cyclic nucleotide phosphodiesterase (PDE4) family. PDE4 enzymes are usually divided into four isoforms (PDE4A, PDE4B, PDE4C, PDE4D), where each isoform has multiple transcription products.

FIGURE 2

Molecular mechanisms of the signaling pathways involved in PDE4B. PDE4B is involved in the PI3K/AKT/mTOR signaling pathway and the other is through specific hydrolysis of cAMP followed by activation of the PKA signaling pathway.